-+ 0.00%
-+ 0.00%
-+ 0.00%

Daewoong Pharmaceutical Presents Phase 1 Clinical Trial Data for New Autoimmune Disease Drug 'Plodicitinib' at ACR Convergence 2026

Barchart·11/17/2026 02:53:00
Listen to the news

SEOUL, South Korea and ORLANDO, Fla., Nov. 17, 2026 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented data from the Phase 1 clinical trial of its new drug candidate for autoimmune diseases, 'Plodicitinib(DWP212525)', at the 'American College of Rheumatology (ACR) Convergence 2026' held on November 9 (local time) in Orlando, Florida.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.